Ieq Capital LLC Buys Shares of 19,500 Chemed Corporation $CHE

Ieq Capital LLC bought a new stake in shares of Chemed Corporation (NYSE:CHE) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 19,500 shares of the company’s stock, valued at approximately $9,082,000.

A number of other hedge funds have also made changes to their positions in CHE. Geneos Wealth Management Inc. increased its stake in shares of Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock worth $61,000 after buying an additional 76 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Chemed by 67.0% in the second quarter. Arrowstreet Capital Limited Partnership now owns 11,365 shares of the company’s stock valued at $5,534,000 after acquiring an additional 4,560 shares in the last quarter. Marshall Wace LLP bought a new position in Chemed during the 2nd quarter valued at $579,000. Brown Advisory Inc. boosted its stake in Chemed by 36.9% during the 2nd quarter. Brown Advisory Inc. now owns 549 shares of the company’s stock valued at $267,000 after acquiring an additional 148 shares during the last quarter. Finally, Cerity Partners LLC boosted its stake in Chemed by 237.7% during the 2nd quarter. Cerity Partners LLC now owns 4,451 shares of the company’s stock valued at $2,165,000 after acquiring an additional 3,133 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Stock Performance

CHE stock opened at $541.33 on Monday. The stock’s 50 day simple moving average is $499.24 and its 200 day simple moving average is $446.50. Chemed Corporation has a 12-month low of $365.20 and a 12-month high of $557.00. The firm has a market cap of $7.08 billion, a P/E ratio of 27.19, a P/E/G ratio of 2.05 and a beta of 0.51. The company has a current ratio of 0.91, a quick ratio of 0.89 and a debt-to-equity ratio of 0.17.

Chemed (NYSE:CHE) last released its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, topping analysts’ consensus estimates of $5.60 by $0.46. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The firm had revenue of $673.25 million during the quarter, compared to the consensus estimate of $665.04 million. During the same quarter in the previous year, the company posted $4.27 earnings per share. The firm’s revenue was up 8.8% on a year-over-year basis. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. As a group, equities research analysts predict that Chemed Corporation will post 23.18 EPS for the current year.

Chemed Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th will be given a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Monday, August 17th. This is an increase from Chemed’s previous quarterly dividend of $0.60. Chemed’s payout ratio is 14.06%.

Analysts Set New Price Targets

Several research firms have recently weighed in on CHE. Oppenheimer boosted their target price on shares of Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings raised shares of Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, July 17th. Royal Bank Of Canada lifted their price target on Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a research note on Thursday, July 30th. Finally, Wall Street Zen raised Chemed from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $530.75.

Insider Activity

In related news, Director Patrick P. Grace sold 190 shares of the stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $532.00, for a total transaction of $101,080.00. Following the sale, the director owned 3,533 shares in the company, valued at $1,879,556. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $539.51, for a total transaction of $1,079,020.00. Following the completion of the transaction, the chief executive officer directly owned 70,418 shares in the company, valued at $37,991,215.18. This represents a 2.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 3,537 shares of company stock valued at $1,782,654. Company insiders own 3.33% of the company’s stock.

Chemed Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.